Skip to main content

View full-text article in PMC

. 2011 Oct 14;17(38):4289–4297. doi: 10.3748/wjg.v17.i38.4289

Table 3.

Bcl-2 expression in gastric cancer cells 48 h after treatment with rAd-p53, oxaliplatin or rAd-p53 plus oxaliplatin

Treatment	Gastric cancer cell line
	rAd-p53 (vp/mL)	OXA (μg/mL)	SGC-7901	BGC-823	HGC-27
OXA	0	3.2	26.32 ± 1.21^e ^a	47.53 ± 1.13^e ^a	56.64 ± 1.33^e ^a
rAd-p53	5 × 10⁶	0	28.62 ± 1.07^c ^a	58.23 ± 1.04^c ^a	61.23 ± 1.07^c ^a
	5 × 10⁷	0	24.34 ± 1.05^c ^a	46.26 ± 1.31^c ^a	49.54 ± 1.14^c ^a
	5 × 10⁸	0	18.62 ± 1.32^c ^a	40.81 ± 1.15^c ^a	47.34 ± 1.06^c ^a
	5 × 10⁹	0	15.37 ± 1.51^c ^a	38.37 ± 1.08^c ^a	44.31 ± 1.03^c ^a
rAd-p53+ OXA	5 × 10⁶	3.2	21.76 ± 1.16^e ^c ^a	35.63 ± 1.41^e ^c ^a	38.18 ± 1.08^e ^c ^a
	5 × 10⁷	3.2	18.34 ± 1.24^e ^c ^a	32.37 ± 1.07^e ^c ^a	35.71 ± 2.02^e ^c ^a
	5 × 10⁸	3.2	16.22 ± 1.02^e ^c ^a	29.27 ± 1.13^e ^c ^a	32.91 ± 1.24^e ^c ^a
	5 × 10⁹	3.2	13.14 ± 1.07^e ^c ^a	26.74 ± 1.02^e ^c ^a	29.84 ± 1.57^e ^c ^a
Control	0	0	38.97 ± 1.06	73.71 ± 2.02	84.03 ± 1.02

^a

P < 0.05 vs control;

^c

P < 0.05, rAd-p53 vs rAd-p53 + oxaliplatin (OXA) with the same dose of rAd-p53;

^e

P < 0.05, OXA vs rAd-p53 + OXA with the same dose of OXA.